Citations

Clear

4564 citation(s) found for "Yu, Virginia".

ASHP and ASHP Foundation Pharmacy Forecast 2025: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems
Hoffman, James M. , Tichy, Eric M. , Shea, Suzanne, Sanborn, Michael, Fox, Erin R. , Torrise, Virginia, Abourjaily, Paul , Cunningham, Francesca , Schweitzer, Pamela, Nelson, Scott D. , Stump, Lisa S, Castro, Harvey, Nesbit, Todd, Scott, Christopher M., Tichy, Eric, DiPiro, Joseph T. , Shea, Suzanne, Hung, Anna , Watanabe, Jonathan Hirohiko , Stump, Lisa S. , Castro, Harvey

Mayo Clinic

American Journal of Health-System Pharmacy | September 27, 2024 | Volume: 82 | Issue: 2 | Pages: 17-47

10.1093/ajhp/zxae280 | PMID 39657700 Get It

Abstract Purpose The 2025 ASHP Pharmacy Forecast report is written to identify and contextualize emerging trends that will influence healthcare, health systems, and the pharmacy profession. It provides recommendations to inform strategic planning that should prompt action by pharmacists and health-system leaders. Methods Drawing on the “wisdom of crowds” concept, a survey was constructed by an advisory committee with 6 themes, each with 7 focused statements and a seventh theme on preparedness (54 survey items in total). A survey panel of 321 pharmacy leaders was purposefully designed to capture opinions from a wide range of pharmacists across the United States. Panelists were asked to consider the likelihood of the statements occurring in the next 5 years as being likely, somewhat likely, somewhat unlikely, or very unlikely to occur. Forecast panelists also assessed health systems’ preparedness (from very unprepared to very prepared) for 12 of the statements. Results The 6 survey themes identified were The Business of Healthcare: Challenges in Health-System Pharmacy, Managing Ultra-High-Cost Drugs, Addressing the Gap in Primary Care, Whole Person Health, Navigating Generative Artificial Intelligence: Opportunity and Risk, and Stabilizing the Pharmacy Workforce. The survey was completed by 269 respondents, yielding an 84% response rate. Descriptive statistics of the survey results were provided to chapter authors to inform commentary and strategic recommendations for each theme. Conclusion The Pharmacy Forecast provides insights on large-scale, long-term trends that will influence healthcare and the pharmacy profession over the years ahead. Insight from the report can stimulate strategic thinking and provides a starting point to proactively position leaders, their teams, and departments for potential future trends.
Open Pectoralis Major Repair: Endobutton Fixation
Tadepalli, Vaibhav, Schwartz, Joshua , Tagliero, Adam J. , Goodloe, J. Brett , Gwathmey, F. Winston , Brockmeier, Stephen F. , Tagliero, Adam , Werner, Brian C.

Mayo Clinic

Video Journal of Sports Medicine | September 26, 2024 | Volume: 4 | Issue: 5 | Pages: No page available

10.1177/26350254241256666 | PMID 40309248 Get It

Background: Rupture of the pectoralis major is most commonly seen with eccentric contraction mechanisms, and surgical options in the setting of acute tear include direct repair, endocortical buttons, suture anchors, and transosseous tunnel fixation. This technique video will detail repair using a unicortical endobutton fixation construct. Indications: Surgical repair is indicated for acute, complete pectoralis major tears; incomplete tears involving rupture of the sternal head with intact clavicular head; and tears in the young, active, high-demand demographic. Delay in diagnosis increases the risk of tendon retraction and fatty atrophy. Recent literature has shown that acute repair is superior to chronic repair in functional outcome, pain relief, and overall cosmesis. Technique Description: A beach-chair position and a deltopectoral approach are used to identify and mobilize the torn and retracted sternal head of the pectoralis major. A No. 2 SutureTape is then passed through the disrupted sternal head in a Krackow fashion to allow for a 6-strand repair. Two of the suture strands are then shuttled through the endocortical button. A drill is used to create a corticectomy for endobutton placement, which is secured into place by sequentially tightening each limb. Two additional endobuttons are placed in a similar fashion to complete the construct. Results: Outcomes studies regarding patients with pectoralis major tendon ruptures who underwent endocortical button fixation reveal that 83% of patients had good or excellent outcomes in a recent systematic review. Another study showed no significant difference in functional outcomes, return to activity, or complication rate with endocortical button fixation compared with other mechanisms of fixation. Discussion/Conclusion: Unicortical endobutton fixation can provide another fixation strategy for acute pectoralis major tears in young, active high-demand individuals. Patient Consent Disclosure Statement: The author(s) attests that consent has been obtained from any patient(s) appearing in this publication. If the individual may be identifiable, the author(s) has included a statement of release or other written form of approval from the patient(s) with this submission for publication.
Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis
Armstrong, April W. , Lim, Henry W., Johnson, Sandra Marchese , Claiborne, W. C. Cole, Kalb, Robert E. , Jakus, Jeannette , Mangold, Aaron R. , Bagel, Jerry , Fretzin, Scott , Sheehan, Michael P. , Krell, James, Reeder, Margo J. , Kartono, Francisca, Bridges, Alisha, Nehal, Umbereen S., Schaecher, Kenneth L., Howard, Leah, Eakin, Guy S. , Báez, Suzette , Bishop, Brooke E., Fitzsimmons, Robert C., Papadopoulos, Maryte , Song, William B. , Linn, Kristin A. , Duffin, Kristina Callis , Mangold, A R , Gelfand, Joel M. , Lim, Henry W. , Feldman, Steven R. , Flowers, Richard Hal , Bhutani, Tina , Durkin, John R. , Kaffenberger, Jessica A. , Takeshita, Junko , Fielding, Eric Jameson , Bishop, B., Fitzsimmons, Robert C. , Hubbard, Rebecca A. , Shin, Daniel B.

Mayo Clinic

JAMA Dermatology | September 25, 2024 | Volume: 160 | Issue: 12 | Pages: 1320

10.1001/jamadermatol.2024.3897 | PMID 39319513 Get It

Importance Office-based phototherapy is cost-effective for psoriasis but difficult to access. Home-based phototherapy is patient preferred but has limited clinical data, particularly in patients with darker skin. Objective To compare the effectiveness of home- vs office-based narrowband UV-B phototherapy for psoriasis. Design, Setting, and Participants The Light Treatment Effectiveness study was an investigator-initiated, pragmatic, open-label, parallel-group, multicenter, noninferiority randomized clinical trial embedded in routine care at 42 academic and private clinical dermatology practices in the US. Enrollment occurred from March 1, 2019, to December 4, 2023, with follow-up through June 2024. Participants were 12 years and older with plaque or guttate psoriasis who were candidates for home- and office-based phototherapy. Interventions Participants were randomized to receive a home narrowband UV-B machine with guided mode dosimetry or routine care with office-based narrowband UV-B for 12 weeks, followed by an additional 12-week observation period. Main Outcomes and Measures The coprimary effectiveness outcomes were Physician Global Assessment (PGA) dichotomized as clear/almost clear skin (score of ≤1) at the end of the intervention period and Dermatology Life Quality Index (DLQI) score of 5 or lower (no to small effect on quality of life) at week 12. Results Of 783 patients enrolled (mean [SD] age, 48.0 [15.5] years; 376 [48.0%] male), 393 received home-based phototherapy and 390 received office-based phototherapy, with 350 (44.7%) having skin phototype (SPT) I/II, 350 (44.7%) having SPT III/IV, and 83 (10.6%) having SPT V/VI. A total of 93 patients (11.9%) were receiving systemic treatment. At baseline, mean (SD) PGA was 2.7 (0.8) and DLQI was 12.2 (7.2). At week 12, 129 patients (32.8%) receiving home-based phototherapy and 100 patients (25.6%) receiving office-based phototherapy achieved clear/almost clear skin, and 206 (52.4%) and 131 (33.6%) achieved DLQI of 5 or lower, respectively. Home-based phototherapy was noninferior to office-based phototherapy for PGA and DLQI in the overall population and across all SPTs. Home-based phototherapy, compared to office-based phototherapy, was associated with better treatment adherence (202 patients [51.4%] vs 62 patients [15.9%]; P < .001), lower burden of indirect costs to patients, and more episodes of persistent erythema (466 of 7957 treatments [5.9%] vs 46 of 3934 treatments [1.2%]; P < .001). Both treatments were well tolerated with no discontinuations due to adverse events. Conclusions and Relevance In this randomized clinical trial, home-based phototherapy was as effective as office-based phototherapy for plaque or guttate psoriasis in everyday clinical practice and had less burden to patients. Trial Registration ClinicalTrials.gov Identifier: NCT03726489
Subclinical coronary artery disease and perioperative cardiac events in patients undergoing peripheral artery bypass surgery
Pritchard, Abiah, Brunton, Nichole , Sharma, Swapna, Young, Michael N. , Henkin, Stanislav , Henkin, Stanislav , Brunton, Nichole E

Mayo Clinic

Vascular Medicine | September 25, 2024 | Volume: 29 | Issue: 6 | Pages: 720-722

10.1177/1358863x241280070 | PMID 39319860 Get It

Experimental Evaluation of Bleeding Complications, Thrombogenicity and Neointimal Characteristics of Prosthetic Patch Materials Used for Carotid Angioplasty
Rhee, Robert Y. , Gloviczki, Péter , Cambria, Robert A., Miller, Virginia M. , Gloviczki, Péter

Mayo Clinic

Cardiovascular Surgery | September 24, 2024 | Volume: 4 | Issue: 6 | Pages: 746-752

10.1177/096721099600400612 | PMID 9013003 Get It

Experiments were designed to compare perioperative blood loss, early thrombogenicity and morphologic and functional characteristics of the neointima of three types of prosthetic materials used for carotid artery patch angioplasty. Bilateral carotid patch angioplasties were performed in 20 dogs, using 20 gelatin-impregnated fluoropassivated Dacron (GIF), 10 untreated knitted Dacron and 10 expanded polytetrafluoroethylene (PTFE) patches (5 cm2). Intraoperative blood loss, platelet deposition at 24 h and neointimal morphology at 6 weeks after the operation were assessed. Bioassay of the neointima was performed at 6 weeks in 16 patches. Mean (s.e.m.) blood loss was significantly less in GIF patches (14.7 (2.7) ml) compared with either PTFE (75.6 (24) ml) or untreated Dacron (64. 3 (9.5)) ( P < 0.005). Mean (s.e.m.) platelet deposition in GIF patches (1380 (328) platelets/cm2) was approximately 50% less at 24 h than in untreated Dacron (2562 (1035) platelets/cm2) or PTFE (2140 (998) platelets/cm2) patches ( P < 0.05). Neointimal coverage was greater in PTFE (94 (1.3%)) compared with GIF (79 (2.7%)) or untreated Dacron (86(2.4%)) patches ( P < 0.05). The thickness of the neointimal layer of PTFE (0.5 (0.01) mm) patches was greater than other patch types; GIF (0.2 (0.01) mm) or untreated Dacron (0.3 (0.01) mm) ( P < 0.05). Under bioassay conditions, acetylcholine caused release of vasoactive relaxing factor(s) from all patches. However, relaxations from baseline were less with GIF patches (−37.9 (11.7)% versus −54.5 (9.6) for untreated Dacron; −50.2 (15.2)% for PTFE) ( P = n.s.). Endothelin-1 release occurred from all patches and was increased with the extent of neointimal coverage. These data demonstrate that GIF patches caused the least perioperative bleeding, were the least thrombogenic at 24 h and developed the thinnest neointima at 6 weeks. All patch materials developed a functioning neointima.
EP050 Anesthetic and analgesic management in outpatient primary knee and hip arthroplasty: a systematic review focused on patient-centered outcomes
Gillespie, Nigel, Ouanes, Jean-Pierre P., Shilling, Ashley , Tokita, Hanae K. , Ardon, Alberto E. , Li, Jinlei , Johnson, Rebecca, Ouanes, Jean-Pierre P. , Wilson, Sylvia H

Mayo Clinic

ePoster session 2 – Station 2 | September 24, 2024 | Volume: No volume available | Issue: No issue available | Pages: A97-A98

10.1136/rapm-2024-esra.123 Get It

Benefits and risks of FDA‐approved amyloid‐targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician‐patient engagement
Rentz, Dorene M., Aisen, Paul, Hitchcock, Janice M., Irizarry, Michael C. , Landen, Jaren W., Matthews, Brandy R., Miller, David S. , Napoli, Salvatore , Okhravi, Hamid , Petersen, Ronald C., Siemers, Eric , Weber, Christopher J., Weisman, David C., Carrillo, María C. , Rentz, Dorene M. , Atri, Alireza , Miller, David S., Mahinrad, Simin , Napoli, Salvatore, Petersen, Ronald C.

Mayo Clinic

Alzheimer's & Dementia | September 22, 2024 | Volume: 20 | Issue: 11 | Pages: 8162-8171

10.1002/alz.14199 | PMID 39306695 Get It

AbstractThe emergence of the United States Food and Drug Administration (FDA)‐approved amyloid‐targeting therapies for Alzheimer's disease challenges clinicians and healthcare providers with a transformative landscape. Effectively communicating the risks, benefits, burdens, costs, and available support associated with these novel disease‐modifying treatments to patients, families, and other healthcare providers is essential but complex. In response, the Alzheimer's Association's Clinical Meaningfulness Workgroup has proposed language surrounding treatment eligibility, benefits, amyloid‐related imaging abnormalities (ARIA), apolipoprotein E (APOE) genotyping, and treatment costs, serving as a resource to healthcare professionals in navigating discussions with patients and their families. As the landscape evolves with the approval of new Alzheimer's therapies, this resource stands poised for updates, ensuring its continued relevance in facilitating informed and meaningful patient‐provider dialogues.Highlights Effective communication of risks, benefits, burdens, and costs of FDA‐approved amyloid‐targeting antibodies is essential to patients, families, and healthcare providers. The Alzheimer's Association's Clinical Meaningfulness Workgroup provides language for physicians and healthcare providers around treatment eligibility, benefits, ARIA, APOE genotyping, and treatment costs. This supplementary resource may be updated as new AD therapies become approved.
Abstract B032: Advancing the science of cancer in Latinos conference
Jones, Rebecca T., Camargo, M. Constanza , Colón‐Otero, Gerardo , Despres, Cliff , Mendoza, Martín, Recio‐Boiles, Alejandro , Segarra-Vázquez, Barbara , Stanford, Sandi, Trapido, Edward , Orozco, Nicolette M, Ramirez, Amelie G , Banegas, Matthew P. , Fejerman, Laura , Lynce, Filipa , Moreno, Patricia I. , Stern, Mariana Carla , Tossas, Katherine Y.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 21, 2024 | Volume: 33 | Issue: 9_Supplement | Pages: B032-B032

10.1158/1538-7755.disp24-b032 Get It

Abstract Cancer is the leading cause of mortality within the Latino population. Projections suggest a 142% increase in cancer incidence among Latinos over the next two decades. This trend is concerning given that Latinos, the largest minority group in the United States, are expected to constitute at least 28% of the nation's populace by 2060. To address the need for enhanced comprehension of these trends and to identify equitable interventions targeting Latino health disparities, the Institute of Health Promotion Research and the Mays Cancer Center jointly established the biennial Advancing the Science of Cancer in Latinos (ASCL) Conference. The fourth ASCL Conference convened in San Antonio, TX from February 21-23, 2024. The conference objectives were twofold: 1) Examine the intersection of health equity and biological underpinnings in cancer control, prevention, and treatment; and 2) Foster collaborative initiatives among attendees aimed at addressing cancer-related health disparities within the Latino community. The 2024 conference attracted 286 participants compared to 251 attendees in 2022, encompassing guest speakers, researchers, physicians, healthcare professionals, patient advocates, researchers, and students. It comprised 23 sessions (3 keynotes, 6 plenaries, 6 breakouts, 3 general sessions, 1 special session, 1 lunch panel session) featuring insights from 51 speakers, alongside a poster session highlighting 80 research abstracts and a rapid-fire session tailored for early-career investigators. Sessions encompassed multiple topics relevant to Latino cancer research, spanning health disparities, clinical trials, survivorship, patient advocacy, climate change impacts on cancer, precision medicine, health policy and social determinants of health. A post-conference survey from a cohort of 48 respondents underscored high levels of satisfaction, with 90% expressing pronounced contentment regarding the conference experience, compared to 85% in 2022. Moreover, nearly all respondents (98%) rated the relevance of conference content to Latino cancer science as excellent, with 93% regarding the conference as an exceptional platform for information exchange, compared to 79% in 2022. Impressions regarding session quality were overwhelmingly positive, with 90% of respondents indicating a high level of satisfaction, and all survey respondents acknowledging the objectivity, balance, and absence of commercial bias in the session content. Our results showed that the resounding positivity in attendee feedback reflects the conference's success in fostering meaningful engagement among researchers committed to alleviating Latino cancer health disparities. The ASCL conference facilitated an understanding of cultural nuances and barriers specific to the Latino community, stimulating collaborative efforts aimed at enhancing Latino health outcomes. Overall, this retrospective analysis affirms the conference's success in achieving its stipulated objectives and underscores the need of having consistently coordinated research endeavors to reduce Latino health disparities. Citation Format: Amelie G. Ramirez, Rebecca T. Jones, Matthew P. Banegas, Maria C Camargo, Gerardo Colon-Otero, Cliff Despres, Laura Fejerman, Filipa Lynce, Martin Mendoza, Patricia I. Moreno, Alejandro Recio-Boiles, Barbara Segarra-Vazquez, Sandi Stanford, Mariana Stern, Katherine Y. Tossas, Edward J. Trapido, Nicolette M Orozco. Advancing the science of cancer in Latinos conference [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr B032.
Improved technical outcomes with converting thrombectomy techniques after failed first pass recanalization
Matsukawa, Hidetoshi , Matouk, Charles , Uchida, Kazutaka , Kasab, Sami Al , Sowlat, Mohammad‐Mahdi , Elawady, Sameh Samir , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M., Psychogios, Marios‐Nikos, Howard, B, Tanweer, Omar , Polifka, Adam , Crosa, Roberto , Park, Min S. , Brinjikji, Waleed , Williamson, Richard , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Yoshimura, Shinichi , Al Kasab, Sami , Rai, Ansaar , Arthur, Adam Stephen , Cuellar-Saenz, Hugo H , Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Levitt, Michael R , Brinjikji, Waleed , Navia, Pedro , Kan, Peter , De Leacy, Reade , Ezzeldin, Mohamad , Spiotta, Alejandro M , Alawieh, Ali M , Matouk, Charles , Wolfe, Stacey Quintero , Matsukawa, Hidetoshi , Sowlat, Mohammad-Mahdi , Jabbour, Pascal , Samaniego, Edgar A , Cuellar, Hugo , Howard, Brian M., Romano, Daniele Giuseppe , Fragata, Isabel , Levitt, Michael R. , Moss, Mark, Navía, Pedro , Leacy, Reade De , Alawieh, Ali

Mayo Clinic

Journal of NeuroInterventional Surgery | September 20, 2024 | Volume: 17 | Issue: 12 | Pages: 1333-1339

10.1136/jnis-2024-022071 | PMID 39304195 Get It

Background A higher number of recanalization attempts reduces the efficacy of endovascular thrombectomy (EVT) for acute ischemic stroke secondary to large vessel occlusion (LVO). We assessed the impact of switching EVT techniques after a failed first pass on procedural and clinical outcomes. Methods This multicenter international study, conducted between January 2013 and December 2022, included patients undergoing EVT for anterior circulation LVO (internal carotid artery or M1 segments) with failed first pass recanalization. Propensity score matching identified a 1:1 matched cohort of patients in whom EVT technique was changed after a failed first pass and those with the same technique repeated. The primary outcome was successful recanalization at second attempt defined as Thrombolysis in Cerebral Ischemia (TICI) score of 2B or higher. Secondary outcomes were 90-day modified Rankin Score (mRS) and postprocedural hemorrhage. Results Among 2167 patients, converting to an alternative technique after a failed first pass was associated with higher odds of successful recanalization (adjusted OR (aOR)=1.5, p=0.041), and higher odds of mRS 0–2 at 90 days (aOR=1.6, p=0.005) without additional risk of symptomatic hemorrhage (p=0.379). Using a propensity score matched cohort of 490 patients, technique conversion at second attempt increased odds of successful recanalization at second attempt (aOR=1.32, p=0.006) and 90-day mRS 0–2 (aOR=1.38, p=0.008). Conclusions Early conversion to an alternative EVT technique after a failed first pass recanalization in patients with AIS is associated with better technical success and clinical outcomes.
Efficacy of Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)) a Treatment for Cancer-related Cognitive Impairment (CRCI): A Randomized Controlled Trial
Reich, Richard R. , Rodriguez, Carmen S., Nguyen, Anh , Meng, Hongdao , Tinsley, Sara , Hueluer, Gizem, Donovan, Kristine A. , Bornstein, Elizabeth, Nidamanur, Sreenidhi, Padgett, Lynne, Lucas, Jean M., Fonseca, Tamela , Joshi, Anisha, Lin, Katherine, Goodman, Matthew , Hülür, Gizem , Tinsley, Sara , Hueluer, Gizem , Lengacher, Cecile A. , Park, Jong Y. , Moscoso, Manolete S. , Kiluk, John V. , Kip, Kevin E.

Mayo Clinic

Journal of Integrative and Complementary Medicine | September 18, 2024 | Volume: 31 | Issue: 1 | Pages: 75-91

10.1089/jicm.2024.0184 | PMID 39291332 Get It

Introduction: The Mindfulness-Based Stress Reduction (MBSR) Program for breast cancer survivors (BCS) is designed to enhance cognitive training through formal and informal meditational practices. This randomized clinical trial (RCT) aimed to evaluate if BCS assigned to either the MBSR(BC), Breast Cancer Education Support (BCES), or Usual Care (UC) regimens experienced greater improvements at 6, 12, and 26 weeks on objective and subjective cognitive performance. Methods: BCS ( n = 212) randomized to a three-group RCT: MBSR(BC) ( n = 91), BCES ( n = 90), or UC ( n = 31) were assessed on cognitive performance and symptoms at baseline, 6, 12, and 26 weeks. Linear mixed models were fit to evaluate the effects of the MBSR(BC) program, hypothesizing ordered effect improvements: (MBSR[BC] highest, BCES intermediate, UC lowest) along with baseline characteristics evaluated as moderators. Results: Of the BCS (mean age of 57), 73% were White, and non-Hispanic, and 77% received both chemotherapy (CT) and radiation. Cognitive performance improved in all groups. Although there were no statistically significant between-group differences in cognitive outcomes, significant symptom reductions occurred for the MBSR(BC) group ( p = 0.003). Within-group effect size analysis at 26 weeks showed substantial improvements in all three groups (effect sizes >0.50) in subjective impairments and quality of life (effect size >0.50) and objective measures of cognitive performance. MBSR(BC) showed the largest within-group effect size in the reduction of fatigue (effect size = 0.81). Effect sizes occurred in the hypothesized direction for 10 of the 18 outcomes. Discussion: Although the MBSR(BC) program did not show significant differences in cognitive performance compared with BCES and UC, all groups improved and reductions in fatigue were beneficial for MBSR(BC). Results suggest that cognitive performance may improve after CT over time considering one’s natural history. Furthermore, BCS enrolled in RCTs may be more motivated to improve their health status (NCT02786797).